Current treatments

Comparison of cyclophosphamide-thalidomide-dexamethasone to bortezomib-cyclophosphamide-dexamethasone as induction therapy for multiple myeloma patients in Brazil. Vigolo S et al. Hematol Oncol Stem Cell Ther. 2017 Jun 15. pii: S1658-3876(17)30082-1. doi: 10.1016/j.hemonc.2017.05.027. [Epub ahead of print]. Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone. Vogl DT et al. Leuk Lymphoma. 2017 Jun 22:1-8. doi: 10.1080/10428194.2017.1334125. [Epub ahead of…

Publication of consensus statement on the use of plerixafor in myeloma or lymphoma patients

A consensus statement identifying the best use of plerixafor to facilitate autologous peripheral stem cell collection to support high-dose therapy and stem cell transplantation in myeloma or lymphoma patients has been published recently in the Journal of Clinical Apheresis. Written by the Plerixafor Usage Working Party Group involving representative clinicians from the UK and Republic…

NICE recommends carfilzomib for restricted use in England and Wales

The National Institute for Health and Care Excellence (NICE) has published a final appraisal determination (FAD) recommending the use of carfilzomib (Kyprolis®) in combination with dexamethasone for myeloma patients at first relapse who have not previously received bortezomib (Velcade®). Carfilzomib will immediately be available to eligible patients in England via interim funding arrangements through the…

IMWG publishes consensus on second primary malignancies in myeloma

The International Myeloma Working Group (IMWG) has published a consensus statement providing practical recommendations for managing myeloma patients who develop second primary malignanices (SPMs). Published in the Annals of Oncology, the group reviewed the latest evidence of possible host-, disease- and treatment-related risk factors for the development of SPMs in myeloma patients. They recommend that…

Diagnostic techniques and prognostic indicators

Identification of pathway-based prognostic gene signatures in patients with multiple myeloma. Zamani-Ahmadmahmudi M et al. Transl Res. 2017 May 9. pii: S1931-5244(17)30041-5. doi: 10.1016/j.trsl.2017.05.001. [Epub ahead of print]. Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy. Łuczak M, Kubicki T et al. Pol Arch Intern Med. 2017 May 25. doi: 10.20452/pamw.4032. [Epub ahead of…

Related conditions

Incidence, characteristics and outcome of solitary plasmacytoma and plasma cell leukemia. Population based data from the Swedish Myeloma Register. Nahi H et al. Eur J Haematol. 2017 May 22. doi: 10.1111/ejh.12907. [Epub ahead of print]. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. Salem DA et al. Leuk Lymphoma. 2017…

Emerging treatments

Haematological cancer: Pembrolizumab is effective in multiple myeloma. Sidaway P. Nat Rev Clin Oncol. 2017 May 23. doi: 10.1038/nrclinonc.2017.76. [Epub ahead of print]. A Phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractorymultiple myeloma. Martin T et al. Blood. 2017 May 8. pii: blood-2016-09-740787. doi: 10.1182/blood-2016-09-740787. [Epub ahead of print]. Pembrolizumab, pomalidomide and low dose dexamethasone for relapsed/refractory multiple myeloma.…

Biology and genetics

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Thanendrarajan S et al. Haematologica. 2017 May 26. pii: haematol.2017.168872. doi: 10.3324/haematol.2017.168872. [Epub ahead of print]. Somatic mutation spectrum in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape compared to multiple myeloma. Mikulasova A et al. Haematologica. 2017 May 26.…

General

Experiences of establishing an academic early phase clinical trials unit. Brown SR et al. Clin Trials. 2017 May 1:1740774517710250. doi: 10.1177/1740774517710250. [Epub ahead of print]. Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy. Harousseau JL et al. J Clin Oncol. 2017 May 19:JCO2017731331. doi: 10.1200/JCO.2017.73.1331. [Epub ahead of print]. Race colors transplantation utilization for multiple myeloma. Majhail NS et al. Cancer. 2017 May…

Supportive treatments

Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy.
Rodrigues GH et al. Lasers Med Sci. 2017 May 16. doi: 10.1007/s10103-017-2211-0. [Epub ahead of print].

G-CSF improves safety when you start the day after autologous transplant in multiple myeloma.
Sborov DW et al. Leuk Lymphoma. 2017 May 16:1-5. doi: 10.1080/10428194.2017.1318436. [Epub ahead of print].